1. |
Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2 444 consecutively treated patients. World J Surg, 2002, 26(8): 879-885.
|
2. |
Shindo ML, Caruana SM, Kandil E, et al. Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement. Head Neck, 2014, 36(10): 1379-1390.
|
3. |
Urken ML, Haser GC, Likhterov I, et al. The impact of metastatic lymph nodes on risk stratification in differentiated thyroid cancer: have we reached a higher level of understanding? Thyroid, 2016, 26(4): 481-488.
|
4. |
Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA, 2017, 317(13): 1338-1348.
|
5. |
Glaser SM, Mandish SF, Gill BS, et al. Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival. Head Neck, 2016, 38 Suppl 1: E2083-E2090.
|
6. |
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med, 2015, 372(7): 621-630.
|
7. |
Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid, 2021, 31(7): 1076-1085.
|
8. |
管小青, 郑向欣, 顾书成, 等. 多学科团队在晚期特殊类型甲状腺癌诊治中的应用价值. 中国普外基础与临床杂志, 2018, 25(9): 1115-1120.
|
9. |
Fallahi P, Ferrari SM, Galdiero MR, et al. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol, 2022, 79: 180-196.
|
10. |
Higashiyama T, Sugino K, Hara H, et al. Phase Ⅱ study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer, 2022, 173: 210-218.
|
11. |
Takahashi S, Kiyota N, Yamazaki T, et al. A phase Ⅱ study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol, 2019, 15(7): 717-726.
|
12. |
Zheng X, Xu Z, Ji Q, et al. A randomized, phase Ⅲ study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. Clin Cancer Res, 2021, 27(20): 5502-5509.
|
13. |
Huang NS, Wei WJ, Xiang J, et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase Ⅱ clinical trial. Thyroid, 2021, 31(12): 1808-1813.
|
14. |
St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology, 2005, 146(3): 1145-1153.
|
15. |
Costa R, Carneiro BA, Chandra S, et al. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther, 2016 Feb 29: 10: 873-84.10-873.
|
16. |
Besic N, Auersperg M, Dremelj M, et al. Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma. Thyroid, 2013, 23(2): 178-184.
|
17. |
Brose MS, Panaseykin Y, Konda B, et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab, 2022, 107(3): 776-787.
|
18. |
Kim M, Ahn J, Song DE, et al. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer. Endocrine, 2021, 71(2): 427-433.
|
19. |
Sukumar JS, Moore W, Khan SA. Therapy with tyrosine kinase inhibitor lenvatinib in radioactive iodine-naive advanced differentiated thyroid cancer. International Journal of Endocrine Oncology, 2019, 6(4): IJE23.
|
20. |
Tahara M, Brose MS, Wirth LJ, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer, 2019, 106: 61-68.
|
21. |
Masaki C, Sugino K, Saito N, et al. Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. Thyroid, 2020, 30(2): 214-221.
|
22. |
Taylor MH, Takahashi S, Capdevila J, et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid, 2021, 31(8): 1226-1234.
|
23. |
Brauckhoff M, Machens A, Thanh PN, et al. Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival. Surgery, 2010, 148(6): 1257-1266.
|
24. |
Gaissert HA, Honings J, Grillo HC, et al. Segmental laryngotracheal and tracheal resection for invasive thyroid carcinoma. Ann Thorac Surg, 2007, 83(6): 1952-1959.
|
25. |
McCaffrey JC. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology. Laryngoscope, 2006, 116(1): 1-11.
|
26. |
Hartl DM, Zago S, Leboulleux S, et al. Resection margins and prognosis in locally invasive thyroid cancer. Head Neck, 2014, 36(7): 1034-1038.
|
27. |
Maurer E, Eilsberger F, Wächter S, et al. Mutation-based, short-term “neoadjuvant” treatment allows resectability in stage ⅣB and C anaplastic thyroid cancer. Eur Arch Otorhinolaryngol, 2023, 280(3): 1509-1518.
|
28. |
Russell M, Gild ML, Wirth LJ, et al. Neoadjuvant therapy to improve resectability of advanced thyroid cancer: a real-world experience. Head Neck, 2024 Mar 15. doi: 10.1002/hed.27735.
|
29. |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer, 2009, 45(2): 228-247.
|
30. |
Brauckhoff M, Machens A, Thanh PN, et al. Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival. Surgery, 2010, 148(6): 1257-1266.
|
31. |
Gaissert HA, Honings J, Grillo HC, et al. Segmental laryngotracheal and tracheal resection for invasive thyroid carcinoma. Ann Thorac Surg, 2007, 83(6): 1952-1959.
|
32. |
Wirth LJ, Tahara M, Robinson B, et al. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer, 2018, 124(11): 2365-2372.
|
33. |
谭宇珊, 刘枫. 碘难治性分化型甲状腺癌靶向治疗研究进展. 中国普外基础与临床杂志, 2023, 30(9): 1130-1137.
|
34. |
McCrary HC, Aoki J, Huang Y, et al. Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol (Oxf), 2022, 96(5): 734-742.
|